

|                               |                    |
|-------------------------------|--------------------|
| <b>Application Number</b>     | 10/712,795         |
| <b>Filing Date</b>            | 11/13/2003         |
| <b>First Named Inventor</b>   | Rosanne M. Crooke  |
| <b>Art Unit</b>               | 1633               |
| <b>Examiner Name</b>          | Janet L. Epps-Ford |
| <b>Attorney Docket Number</b> | DOC-0216US         |

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

|   |                        |                          |                    |
|---|------------------------|--------------------------|--------------------|
| Substitute for form 1449/PTO  |                        | <b>Complete if Known</b> |                    |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |                        | Application Number       | 10/712,795         |
|   |                        | Filing Date              | 11/13/2003         |
|   |                        | First Named Inventor     | Rosanne M. Crooke  |
|   |                        | Art Unit                 | 1633               |
|   |                        | Examiner Name            | Janet L. Epps-Ford |
| Sheet 2 of 2  | Attorney Docket Number | DOC-0216US               |                    |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials *             | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
| /JE/                            | DK                    | AGRAWAL, S. et al., "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Mol. Med. Today</i> (2000) 6:72-81.   |                |
|                                 | DL                    | CROOKE, S. T., "Basic Principles of Antisense Therapeutics," <i>Antisense Research and Application</i> (1998) Springer-Verlag Press, Berlin, pp 1-50.   |                |
|                                 | DM                    | EMBL Accession No. L27195, January 6, 1994.   |                |
|                                 | DN                    | GRAHAM, M. J. et al., "Inhibition of ApoB-100 as a Therapeutic Strategy for the Treatment of Hyperlipidemias," <i>AHA Abstracts</i> (2002).   |                |
|                                 | DO                    | HUANG, L.-S. et al., "Hypobetalipoproteinemia Due to an Apolipoprotein B Gene Exon 21 Deletion Derived by Alu-Alu Recombination," <i>J. Biol. Chem.</i> (1969) 264(19):11394-11400.   |                |
|                                 | DP                    | JEN, K.-Y. et al., "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> (2000) 18:307-319.   |                |
|                                 | DQ                    | LATORRA, D. et al., "Enhanced Allele-Specific PCR Discrimination in SNP Genotyping Using 3' Locked Nucleic Acid (LNA) Primers," <i>Hum. Mutat.</i> (2003) 22:79-85.   |                |
|                                 | DR                    | MA, D. D. F. et al., "Synthetic oligonucleotides as therapeutics: the coming of age," <i>Biotech. Ann. Rev.</i> (2000) 5:155-196.   |                |
|                                 | DS                    | NOWAK-GÖTTL, U. et al., "Lipoprotein (a): Its Role in Childhood Thromboembolism," <i>Pediatrics</i> (1997) 99(6):1-3.   |                |
|                                 | DT                    | ROSSI, J. J. et al., "Introductory Remarks on the General Application of Antisense RNAs and Ribozymes," <i>Methods Enzym.</i> (1993) 5:1-5.   |                |
|                                 | DU                    | SKRAPARI, L. et al., "Glibenclamide improves postprandial hypertriglyceridaemia in Type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels," <i>Diabetic Med.</i> (2001) 18:781-785.                      |                |
| /JE/                            | DV                    | TANAKA, M et al. "Regulation of Apolipoprotein B Production and Secretion in Response to the Change of Intracellular Cholesteryl Ester Contents in Rabbit Hepatocytes," <i>J. Biol. Chem.</i> (1993) 268(17):12713-12718.                                       |                |
|                                 |                       |   |                |

|                    |                   |                 |            |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /Janet Epps Ford/ | Date Considered | 07/19/2007 |
|--------------------|-------------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.